Dugan W, McDonald M V, Passik S D, Rosenfeld B D, Theobald D, Edgerton S
Community Cancer Care, Inc., Indianapolis, IN, USA.
Psychooncology. 1998 Nov-Dec;7(6):483-93. doi: 10.1002/(SICI)1099-1611(199811/12)7:6<483::AID-PON326>3.0.CO;2-M.
The feasibility, utility and reliability of the Zung Self-Rating Depression Scale (ZSDS) was examined in a large sample of ambulatory cancer patients. This tool and a brief 11-item version of the ZSDS (excluding nine items concerning somatic symptoms), which was developed during the course of the survey, were used to estimate the prevalence of self-reported depressive symptoms. Patient characteristics that may be associated with an increased risk of clinically significant depressive symptoms were also explored. Twenty-five ambulatory oncology clinics affiliated with Community Cancer Care, Inc. enrolled and surveyed 1109 subjects. The alpha coefficients for the ZSDS (0.84) and the Brief ZSDS (0.84) indicated high levels of internal consistency. The overall prevalence of clinically significant depressive symptoms as defined by the ZSDS was 35.9% and by the Brief ZSDS was 31.1%. The ZSDS and the Brief ZSDS were highly correlated (r = 0.92). The medical and demographic variables most associated with clinically significant depressive symptoms were more advanced stage of disease at time of diagnosis, lung cancer as primary tumor type, higher ECOG rating (greater degree of physical disability), and having been prescribed antidepressant medications. The high prevalence of depressive symptoms observed in this study is consistent with rates found in other studies of self-report depression instruments in cancer patients. The initial indicators of internal consistency and validity suggest that the Zung SDS or the brief version may be useful screening tools to identify depressive symptoms in oncology patients.
在一大群门诊癌症患者样本中，对zung自评抑郁量表（ZSDS）的可行性、实用性和可靠性进行了检验。在调查过程中开发了该工具以及一个简短的11项版本的ZSDS（不包括9项有关躯体症状的条目），用于估计自我报告的抑郁症状的患病率。还探讨了可能与临床上显著抑郁症状风险增加相关的患者特征。隶属于社区癌症护理公司的25家门诊肿瘤诊所招募并调查了1109名受试者。ZSDS（0.84）和简短ZSDS（0.84）的α系数表明内部一致性水平较高。由ZSDS定义的临床上显著抑郁症状的总体患病率为35.9%，由简短ZSDS定义的为31.1%。ZSDS和简短ZSDS高度相关（r = 0.92）。与临床上显著抑郁症状最相关的医学和人口统计学变量是诊断时疾病分期更晚、原发性肿瘤类型为肺癌、ECOG评分更高（身体残疾程度更高）以及曾被开具抗抑郁药物。本研究中观察到的抑郁症状高患病率与其他关于癌症患者自我报告抑郁工具的研究中发现的患病率一致。内部一致性和有效性的初步指标表明，zung SDS或简短版本可能是识别肿瘤患者抑郁症状的有用筛查工具。
